Aeromonas — Symbiont & Clinical Pathogen
Dominant gut symbiont and primary cause of leech-associated infections
Aeromonas safety context: Infection prophylaxis is the dominant safety question in real-world leech use. See the Coverage Map for clinical-evidence coverage, the Research Roadmap for resistance-surveillance priorities, and Transparency & Trust for the editorial-integrity record.
November 1, 2026
Aeromonas veronii biovar sobria is the dominant bacterial symbiont in the medicinal leech gut, which, together with Mucinivorans hirudinis, dominates the gut microbiome (the two species make up over 95% of the gut community). It is also the primary pathogen in leech-associated infections, accounting for about 88% of leech-associated infections in a systematic review of 277 reported cases (Whitaker 2012); infection rates of 2.4–36.2% of treated patients have been reported.
Biology of Aeromonas veronii
- Taxonomy: Gram-negative, facultative anaerobe, motile rod (polar flagellum)
- Family: Aeromonadaceae (Gammaproteobacteria)
- Habitat: Aquatic environments (freshwater, estuarine); commensal in leech gut
- Vertical transmission: Passed from mother to offspring via cocoons (not acquired from environment post-hatching)
- Virulence factors: Type IV secretion system, quorum sensing (AHL-based), hemolysin production, siderophores for iron acquisition
The leech-Aeromonas symbiosis is obligate for the leech: without Aeromonas, leeches cannot digest blood efficiently and show reduced growth and reproduction.
Infection in Patients
Incidence
- Without prophylaxis: 7-20% infection rate in most published series
- With prophylaxis (ciprofloxacin or TMP-SMX): 11.9% surgical-site infection in one multicenter cohort (7/59 patients; all infected patients had received prophylaxis), significantly less frequent than without prophylaxis
Clinical Presentations
- Localized cellulitis: Mildest presentation — erythema, warmth, tenderness at bite site
- Abscess formation: A more serious presentation — requires incision & drainage
- Necrotizing fasciitis: Rare but serious — requires surgical debridement
- Sepsis: Rare — fatal cases reported in critically ill patients
Risk Factors for Infection
- Immunosuppression: Chemotherapy, transplant recipients, HIV/AIDS
- Diabetes mellitus: Impaired wound healing + immune dysfunction
- Peripheral vascular disease: Poor tissue perfusion
- Chronic corticosteroid use: Suppresses inflammatory response
- Advanced age: Immunosenescence
Antibiotic Prophylaxis
Standard of care: All patients receiving medicinal leech therapy should receive antibiotic prophylaxis targeting Aeromonas.
Recommended Regimens
- Ciprofloxacin: 500 mg PO BID (among the most commonly recommended agents)
- Trimethoprim-sulfamethoxazole (Bactrim): DS tablet PO BID (alternative for quinolone allergy)
- Duration: During leech therapy + about 1 week post-treatment (published protocols range from 24 hours to 2 weeks)
Resistance Concerns
Growing ciprofloxacin resistance has been documented in multiple studies (Beka et al., mBio, 2018). This is likely due to:
- Low-level antimicrobials naturally present in leech SGS
- Selective pressure from prophylactic antibiotic use
- Horizontal gene transfer within the leech microbiome
Antimicrobial Sensitivity Profile
| Drug | Sensitivity | Notes |
|---|---|---|
| Ciprofloxacin | Usually sensitive | Growing resistance (28.6% of Aeromonas isolates from one leech-tank surveillance were not ciprofloxacin-susceptible) |
| TMP-SMX | Usually sensitive | Alternative to quinolones |
| Tetracycline/Doxycycline | Usually sensitive | Third-line option |
| Ceftriaxone (3rd-gen ceph) | Usually sensitive | IV option for severe infections |
| Ampicillin | Resistant | Natural resistance (β-lactamase) |
| 1st-gen cephalosporins | Resistant | Do not use |
Prevention Beyond Antibiotics
Comprehensive infection prevention includes:
- Single-use policy: Never reuse leeches (cross-contamination risk)
- Proper wound care: Sterile technique during application, appropriate dressing changes
- Patient screening: Identify immunosuppression, diabetes, vascular disease before therapy
- Monitoring: Daily assessment for 7-10 days post-treatment (erythema, warmth, purulence)
- Patient education: Instruct on signs of infection, when to seek care